Related Experiment Video

Updated: Jun 24, 2026

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction

Marc-Michael Zaruba1, Hans Diogenes Theiss, Markus Vallaster

  • 1Medical Department I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.

Cell Stem Cell
|April 4, 2009
PubMed

Insights

Stem cell therapy for ischemic cardiomyopathy shows promise. Inhibiting DPP-IV and mobilizing stem cells improved heart function and survival in mice by enhancing stem cell homing to the heart.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Ischemic cardiomyopathy is a leading cause of mortality.
  • Stem cell-based therapies offer potential prevention strategies.
  • Stem cell homing to the heart is crucial for therapeutic efficacy.

Purpose of the Study:

  • To investigate a novel therapeutic strategy for ischemic cardiomyopathy.
  • To combine DPP-IV inhibition with G-CSF-mediated stem cell mobilization.
  • To evaluate the impact on cardiac remodeling and function in a mouse model.

Main Methods:

  • Utilized a mouse model of myocardial infarction.
  • Combined genetic/pharmacologic DPP-IV inhibition with G-CSF stem cell mobilization.
  • Assessed myocardial DPP-IV activity, stem cell homing (CXCR-4+), cardiac remodeling, and heart function.

Main Results:

  • Decreased myocardial DPP-IV activity was observed.
  • Enhanced homing of circulating stem cells to the myocardium.
  • Reduced cardiac remodeling and improved heart function and survival.
  • CD26 depletion stabilized active SDF-1alpha and preserved the SDF-1-CXCR4 axis.

Conclusions:

  • Pharmacological DPP-IV inhibition combined with G-CSF stem cell mobilization is a viable therapeutic concept.
  • This approach enhances stem cell homing and improves outcomes after myocardial infarction.
  • This strategy holds promise for future clinical stem cell trials in ischemic heart disease.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...